

# Jia Fan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/75905/publications.pdf>

Version: 2024-02-01

418  
papers

26,290  
citations

10956

71  
h-index

10127

140  
g-index

440  
all docs

440  
docs citations

440  
times ranked

33253  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
2	Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 6212-6222.	3.2	1,012
3	Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. <i>Cell</i> , 2019, 179, 561-577.e22.	13.5	629
4	Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. <i>Nature</i> , 2019, 567, 257-261.	13.7	613
5	Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. <i>Gastroenterology</i> , 2016, 150, 1646-1658.e17.	0.6	586
6	FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3/CCL2 Signaling. <i>Cancer Research</i> , 2016, 76, 4124-4135.	0.4	470
7	Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2/3 study. <i>Lancet Oncology</i> , The, 2021, 22, 977-990.	5.1	459
8	STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. <i>Molecular Cancer</i> , 2017, 16, 136.	7.9	434
9	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). <i>Liver Cancer</i> , 2020, 9, 682-720.	4.2	427
10	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). <i>Liver Cancer</i> , 2018, 7, 235-260.	4.2	426
11	Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2018, 154, 128-139.	0.6	417
12	A decade's studies on metastasis of hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 187-196.	1.2	406
13	Hsa_circ_0001649: A circular RNA and potential novel biomarker for hepatocellular carcinoma. <i>Cancer Biomarkers</i> , 2016, 16, 161-169.	0.8	402
14	Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. <i>Cell</i> , 2021, 184, 404-421.e16.	13.5	399
15	Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNBN1. <i>Hepatology</i> , 2016, 63, 499-511.	3.6	332
16	Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. <i>Hepatology</i> , 2013, 57, 1458-1468.	3.6	331
17	Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. <i>Nature</i> , 2018, 559, 637-641.	13.7	327
18	Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. <i>Hepatology</i> , 2012, 56, 2242-2254.	3.6	298

#	ARTICLE	IF	CITATIONS
19	Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level. <i>Cancer Discovery</i> , 2022, 12, 134-153.	7.7	286
20	2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 452-463.	0.7	267
21	N6-Methyladenosine methyltransferase ZCCHC4 mediates ribosomal RNA methylation. <i>Nature Chemical Biology</i> , 2019, 15, 88-94.	3.9	258
22	High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. <i>Gut</i> , 2010, 59, 953-962.	6.1	238
23	Hepatic RIG-I Predicts Survival and Interferon- $\gamma$ Therapeutic Response in Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2014, 25, 49-63.	7.7	182
24	Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. <i>Clinical Cancer Research</i> , 2018, 24, 2074-2081.	3.2	181
25	Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. <i>Gut</i> , 2019, 68, 2195-2205.	6.1	180
26	Landscape and Regulation of m6A and m6Am Methylome across Human and Mouse Tissues. <i>Molecular Cell</i> , 2020, 77, 426-440.e6.	4.5	179
27	Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. <i>International Journal of Oncology</i> , 2015, 46, 587-596.	1.4	177
28	Circular RNA circTRIM33 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression. <i>Molecular Cancer</i> , 2019, 18, 105.	7.9	172
29	Circular RNA Sequencing Identifies CircASAP1 as a Key Regulator in Hepatocellular Carcinoma Metastasis. <i>Hepatology</i> , 2020, 72, 906-922.	3.6	170
30	miR-28a-5p and miR-34a-5p macrophage feedback loop modulates hepatocellular carcinoma metastasis. <i>Hepatology</i> , 2016, 63, 1560-1575.	3.6	166
31	CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3 $\beta$ /Snail signaling. <i>Cancer Letters</i> , 2015, 358, 124-135.	3.2	157
32	The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma. <i>Nature Communications</i> , 2018, 9, 1572.	5.8	157
33	Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy. <i>Theranostics</i> , 2018, 8, 2329-2347.	4.6	155
34	Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1155-1163.	1.2	154
35	CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110 $\beta$ and predicts poor prognosis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 37.	6.9	150
36	Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. <i>Molecular Cancer</i> , 2020, 19, 92.	7.9	147

#	ARTICLE	IF	CITATIONS
37	Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection. <i>Clinical Cancer Research</i> , 2008, 14, 3850-3859.	3.2	143
38	A Positive Feedback Loop Between Cancer Stem-Like Cells and Tumor-Associated Neutrophils Controls Hepatocellular Carcinoma Progression. <i>Hepatology</i> , 2019, 70, 1214-1230.	3.6	140
39	International consensus statement on robotic hepatectomy surgery in 2018. <i>World Journal of Gastroenterology</i> , 2019, 25, 1432-1444.	1.4	134
40	Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 896-908.	1.8	124
41	CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery. <i>Clinical Cancer Research</i> , 2009, 15, 5518-5527.	3.2	122
42	Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. <i>Cancer Cell</i> , 2022, 40, 70-87.e15.	7.7	120
43	Tumor-Induced Generation of Splenic Erythroblast-like Ter-Cells Promotes Tumor Progression. <i>Cell</i> , 2018, 173, 634-648.e12.	13.5	118
44	Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3843-3851.	1.0	117
45	Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients. <i>BMC Cancer</i> , 2018, 18, 1148.	1.1	113
46	Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 547-559.	3.2	112
47	Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated With Tumor Recurrence in Patients. <i>Gastroenterology</i> , 2014, 146, 1397-1407.	0.6	111
48	MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. <i>Carcinogenesis</i> , 2013, 34, 2071-2079.	1.3	109
49	Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 3304-3316.	3.2	109
50	Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. <i>Liver Cancer</i> , 2021, 10, 320-329.	4.2	108
51	Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents. <i>Gastroenterology</i> , 2017, 152, 232-242.e4.	0.6	107
52	Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. <i>Cell Research</i> , 2018, 28, 359-373.	5.7	106
53	CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 143-159.	3.6	105
54	Changing epidemiology of hepatocellular carcinoma in Asia. <i>Liver International</i> , 2022, 42, 2029-2041.	1.9	105

#	ARTICLE	IF	CITATIONS
55	Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2203-2213.	3.2	102
56	Clinical Significance of <i>EpCAM</i> mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR-Based Platform. <i>Clinical Cancer Research</i> , 2014, 20, 4794-4805.	3.2	99
57	Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1403-1412.	1.2	95
58	A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of <i>GLI1</i> mRNA. <i>Cancer Letters</i> , 2019, 450, 98-109.	3.2	94
59	Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning. <i>Gut</i> , 2021, 70, 951-961.	6.1	93
60	Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2019, 19, 71.	1.8	92
61	HNRNPAB Induces Epithelial-Mesenchymal Transition and Promotes Metastasis of Hepatocellular Carcinoma by Transcriptionally Activating <i>SNAIL</i> . <i>Cancer Research</i> , 2014, 74, 2750-2762.	0.4	91
62	Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 4091.	5.8	90
63	Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2020, 271, 534-541.	2.1	88
64	Chromatin Remodeling Factor LSH Drives Cancer Progression by Suppressing the Activity of Fumarate Hydratase. <i>Cancer Research</i> , 2016, 76, 5743-5755.	0.4	85
65	Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity. <i>Journal of Cancer</i> , 2016, 7, 1907-1914.	1.2	84
66	Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. <i>Cell Discovery</i> , 2020, 6, 90.	3.1	84
67	PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 846-861.	0.8	84
68	Screening and Identifying a Novel ssDNA Aptamer against Alpha-fetoprotein Using CE-SELEX. <i>Scientific Reports</i> , 2015, 5, 15552.	1.6	83
69	Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. <i>Journal of Cancer Research and Clinical Oncology</i> , 2000, 126, 57-61.	1.2	80
70	Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 293-301.	1.8	79
71	MicroRNA-30a suppresses autophagy-mediated anoikis resistance and metastasis in hepatocellular carcinoma. <i>Cancer Letters</i> , 2018, 412, 108-117.	3.2	79
72	Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target. <i>BMC Cancer</i> , 2019, 19, 760.	1.1	78

#	ARTICLE	IF	CITATIONS
73	miR-612 suppresses the stemness of liver cancer via Wnt/ $\beta$ -catenin signaling. <i>Biochemical and Biophysical Research Communications</i> , 2014, 447, 210-215.	1.0	77
74	EBV-LMP1 suppresses the DNA damage response through DNA-PK/AMPK signaling to promote radioresistance in nasopharyngeal carcinoma. <i>Cancer Letters</i> , 2016, 380, 191-200.	3.2	72
75	The miR-561-5p/CX <sub>3</sub> CR1 Signaling Axis Regulates Pulmonary Metastasis in Hepatocellular Carcinoma Involving CX <sub>3</sub> CR1 <sup>+</sup> Natural Killer Cells Infiltration. <i>Theranostics</i> , 2019, 9, 4779-4794.	4.6	72
76	Lectin-based glycoproteomics to explore and analyze hepatocellular carcinoma-related glycoprotein markers. <i>Electrophoresis</i> , 2009, 30, 2957-2966.	1.3	69
77	MiR-302c inhibits tumor growth of hepatocellular carcinoma by suppressing the endothelial-mesenchymal transition of endothelial cells. <i>Scientific Reports</i> , 2014, 4, 5524.	1.6	68
78	miR-296-5p suppresses EMT of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3 signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 294.	3.5	68
79	Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases. <i>Hepatology International</i> , 2020, 14, 437-453.	1.9	68
80	Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. <i>World Journal of Gastroenterology</i> , 2001, 7, 28.	1.4	68
81	Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 200.	6.9	68
82	Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1243-1255.	0.4	67
83	MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis. <i>Cell Death and Disease</i> , 2017, 8, e2906-e2906.	2.7	66
84	Neolbaconol induces cell death through necroptosis by regulating RIPK-dependent autocrine TNF $\alpha$ and ROS production. <i>Oncotarget</i> , 2015, 6, 1995-2008.	0.8	66
85	IFN $\gamma$ Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment. <i>Cancer Discovery</i> , 2022, 12, 1718-1741.	7.7	66
86	Sequestosome 1/p62 Protein Is Associated with Autophagic Removal of Excess Hepatic Endoplasmic Reticulum in Mice. <i>Journal of Biological Chemistry</i> , 2016, 291, 18663-18674.	1.6	65
87	DNMT1 mediates metabolic reprogramming induced by Epstein-Barr virus latent membrane protein 1 and reversed by grifolin in nasopharyngeal carcinoma. <i>Cell Death and Disease</i> , 2018, 9, 619.	2.7	65
88	Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. <i>Cell Death and Disease</i> , 2020, 11, 573.	2.7	65
89	Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis. <i>World Journal of Gastroenterology</i> , 2005, 11, 1215.	1.4	65
90	Hepatic stellate cells activated by acidic tumor microenvironment promote the metastasis of hepatocellular carcinoma via osteopontin. <i>Cancer Letters</i> , 2015, 356, 713-720.	3.2	64

#	ARTICLE	IF	CITATIONS
91	Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target. <i>Oncotarget</i> , 2014, 5, 7820-7832.	0.8	63
92	Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2018, 69, 89-98.	1.8	63
93	Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2016, 7, 1798-1803.	1.2	62
94	Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2022, 76, 608-618.	1.8	62
95	Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine. <i>Journal of Integrative Medicine</i> , 2018, 16, 236-248.	1.4	61
96	Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. <i>Theranostics</i> , 2019, 9, 4678-4687.	4.6	61
97	Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. <i>British Journal of Cancer</i> , 2016, 114, 767-776.	2.9	60
98	A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2015, 468, 525-532.	1.0	59
99	Chinese Water-Pipe Smoking and the Risk of COPD. <i>Chest</i> , 2014, 146, 924-931.	0.4	58
100	Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 56.	7.1	57
101	CircRPN2 Inhibits Aerobic Glycolysis and Metastasis in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2022, 82, 1055-1069.	0.4	57
102	Hepatic IFIT3 predicts interferon- $\alpha$ therapeutic response in patients of hepatocellular carcinoma. <i>Hepatology</i> , 2017, 66, 152-166.	3.6	56
103	Circulating CD14 <sup>+</sup> HLA <sup>-</sup> DR <sup>low</sup> myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. <i>Hepatology Research</i> , 2017, 47, 1061-1071.	1.8	56
104	Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1 $\alpha$ in lung cancer. <i>Theranostics</i> , 2018, 8, 4050-4061.	4.6	56
105	Cancer-associated fibroblast-derived CXCL11 modulates hepatocellular carcinoma cell migration and tumor metastasis through the circUBAP2/miR-4756/IFIT1/3 axis. <i>Cell Death and Disease</i> , 2021, 12, 260.	2.7	56
106	Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3. , 2021, 9, e001946.		55
107	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 227-252.	0.7	55
108	Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 387-396.	0.7	54



#	ARTICLE	IF	CITATIONS
109	Spatial omics: Navigating to the golden era of cancer research. <i>Clinical and Translational Medicine</i> , 2022, 12, e696.	1.7	53
110	MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming. <i>Journal of Hematology and Oncology</i> , 2020, 13, 12.	6.9	52
111	Using deep learning to predict microvascular invasion in hepatocellular carcinoma based on dynamic contrast-enhanced MRI combined with clinical parameters. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3757-3767.	1.2	52
112	PKC $\zeta$ /ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 163-176.	1.8	52
113	New-onset diabetes after liver transplantation and its impact on complications and patient survival. <i>Journal of Diabetes</i> , 2015, 7, 881-890.	0.8	51
114	42,573 cases of hepatectomy in China: a multicenter retrospective investigation. <i>Science China Life Sciences</i> , 2018, 61, 660-670.	2.3	51
115	Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018). <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 725-736.	1.2	51
116	Plasma hsa_circ_0027089 is a diagnostic biomarker for hepatitis B virus-related hepatocellular carcinoma. <i>Carcinogenesis</i> , 2020, 41, 296-302.	1.3	51
117	CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5 $\beta$ -LSD1 $\beta$ -NF $\kappa$ B oncogenic signaling. <i>Clinical and Translational Medicine</i> , 2020, 10, e233.	1.7	51
118	Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 2539-2548.	0.8	50
119	miR-504 mediated down-regulation of nuclear respiratory factor 1 leads to radio-resistance in nasopharyngeal carcinoma. <i>Oncotarget</i> , 2015, 6, 15995-16018.	0.8	50
120	Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epidermal growth factor receptor $\alpha$ -induced epithelial $\rightarrow$ mesenchymal transition. <i>Hepatology</i> , 2015, 62, 1201-1214.	3.6	49
121	BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma. <i>International Journal of Immunopathology and Pharmacology</i> , 2015, 28, 36-44.	1.0	49
122	Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence. <i>Journal of Hepatology</i> , 2019, 71, 1152-1163.	1.8	49
123	Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study. <i>Cancer</i> , 2018, 124, 2161-2168.	2.0	47
124	Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult. <i>Cancer Research</i> , 2018, 78, 5548-5560.	0.4	47
125	miR-612 suppresses stem cell-like property of hepatocellular carcinoma cells by modulating Sp1/Nanog signaling. <i>Cell Death and Disease</i> , 2016, 7, e2377-e2377.	2.7	46
126	RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2014, 5, 11604-11619.	0.8	46



#	ARTICLE	IF	CITATIONS
127	Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. <i>Theranostics</i> , 2018, 8, 5690-5702.	4.6	45
128	Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. <i>Oncotarget</i> , 2016, 7, 70654-70668.	0.8	44
129	Long noncoding <scp>RNA </scp> <i>SchLAH</i> suppresses metastasis of hepatocellular carcinoma through interacting with fused in sarcoma. <i>Cancer Science</i> , 2017, 108, 653-662.	1.7	44
130	Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion. <i>Oncologist</i> , 2019, 24, 513-520.	1.9	44
131	The long noncoding RNA NORAD enhances the TGF $\beta$ <sup>2</sup> pathway to promote hepatocellular carcinoma progression by targeting miR-202a-5p. <i>Journal of Cellular Physiology</i> , 2019, 234, 12051-12060.	2.0	44
132	Nomograms for survival prediction in patients undergoing liver resection for hepatitis B virus related early stage hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2016, 62, 86-95.	1.3	43
133	Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. <i>Hepatology</i> , 2017, 65, 1948-1962.	3.6	43
134	miR-17-5p and miR-20a-5p suppress postoperative metastasis of hepatocellular carcinoma via blocking HGF/ERBB3-NF- $\kappa$ B positive feedback loop. <i>Theranostics</i> , 2020, 10, 3668-3683.	4.6	43
135	Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. <i>Biomarker Research</i> , 2021, 9, 19.	2.8	43
136	Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics. <i>Hepatology</i> , 2022, 76, 317-329.	3.6	43
137	First in-human intraoperative imaging of HCC using the fluorescence goggle system and transarterial delivery of near-infrared fluorescent imaging agent: a pilot study. <i>Translational Research</i> , 2013, 162, 324-331.	2.2	42
138	Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B. <i>BMC Cancer</i> , 2017, 17, 58.	1.1	42
139	NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells. <i>Journal of Hematology and Oncology</i> , 2018, 11, 28.	6.9	41
140	Overexpression of RNF38 facilitates TGF- $\beta$ <sup>2</sup> signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 113.	3.5	41
141	New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection. <i>Journal of Surgical Oncology</i> , 2018, 117, 1540-1547.	0.8	40
142	Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma. <i>Nature Communications</i> , 2022, 13, 1642.	5.8	40
143	Lamp2a is required for tumor growth and promotes tumor recurrence of hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2016, 49, 2367-2376.	1.4	39
144	Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection. <i>Oncotarget</i> , 2017, 8, 13293-13303.	0.8	39

#	ARTICLE	IF	CITATIONS
145	Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity. <i>Oncotarget</i> , 2016, 7, 2867-2877.	0.8	38
146	microRNA-501-3p suppresses metastasis and progression of hepatocellular carcinoma through targeting LIN7A. <i>Cell Death and Disease</i> , 2018, 9, 535.	2.7	38
147	Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus. <i>Annals of Surgical Oncology</i> , 2018, 25, 2098-2104.	0.7	38
148	CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity. <i>Molecular Cancer</i> , 2021, 20, 75.	7.9	37
149	Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway. <i>Oncotarget</i> , 2016, 7, 75210-75220.	0.8	36
150	Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00006.	1.3	36
151	MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. <i>Cancer Letters</i> , 2019, 459, 156-167.	3.2	36
152	Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells. <i>Cell Reports</i> , 2016, 17, 2979-2993.	2.9	35
153	Liver Stiffness Assessed by Shear Wave Elastography Predicts Postoperative Liver Failure in Patients with Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1471-1479.	0.9	35
154	Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection. <i>Oncologist</i> , 2017, 22, 561-569.	1.9	35
155	Neolbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production. <i>Molecular Carcinogenesis</i> , 2017, 56, 1414-1426.	1.3	35
156	CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. <i>Oncotarget</i> , 2017, 8, 5135-5148.	0.8	35
157	Circulating cell-free DNA for cancer early detection. <i>Innovation(China)</i> , 2022, 3, 100259.	5.2	35
158	Overexpression of semaphorin 3A promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma after curative resection. <i>Oncotarget</i> , 2016, 7, 51733-51746.	0.8	34
159	CK7/CK19 index: A potential prognostic factor for postoperative intrahepatic cholangiocarcinoma patients. <i>Journal of Surgical Oncology</i> , 2018, 117, 1531-1539.	0.8	34
160	Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: a study based on large-scale sequencing data. <i>Carcinogenesis</i> , 2019, 40, 1077-1085.	1.3	34
161	Hepatic stellate cells promote the progression of hepatocellular carcinoma through microRNA-1246-ROR1 $\pm$ -Wnt/ $\beta$ <sup>2</sup> -Catenin axis. <i>Cancer Letters</i> , 2020, 476, 140-151.	3.2	34
162	CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 331.	2.7	34

#	ARTICLE	IF	CITATIONS
163	Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition. <i>Hepatology</i> , 2015, 62, 1804-1816.	3.6	33
164	Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 10-10.	12.5	33
165	A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. <i>Genes and Diseases</i> , 2019, 6, 419-430.	1.5	33
166	EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the <i>RIP3</i> promoter. <i>Theranostics</i> , 2019, 9, 2424-2438.	4.6	33
167	Cystathionine $\beta$ -synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis. , 2021, 9, e003031.		33
168	Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 169-178.	0.7	32
169	FOXP3 Is a HCC suppressor gene and Acts through regulating the TGF- $\beta$ /Smad2/3 signaling pathway. <i>BMC Cancer</i> , 2017, 17, 648.	1.1	32
170	AGO1 may influence the prognosis of hepatocellular carcinoma through TGF- $\beta$ pathway. <i>Cell Death and Disease</i> , 2018, 9, 324.	2.7	32
171	Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. <i>International Journal of Cancer</i> , 2020, 146, 1606-1617.	2.3	32
172	Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. <i>Liver International</i> , 2021, 41, 562-573.	1.9	32
173	The diagnostic value of plasma exosomal <i>hsa_circ_0070396</i> for hepatocellular carcinoma. <i>Biomarkers in Medicine</i> , 2021, 15, 359-371.	0.6	32
174	RANKL Promotes Migration and Invasion of Hepatocellular Carcinoma Cells via NF- $\kappa$ B-Mediated Epithelial-Mesenchymal Transition. <i>PLoS ONE</i> , 2014, 9, e108507.	1.1	32
175	Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence of female patients after curative resection of hepatocellular carcinoma. <i>Surgery</i> , 2014, 156, 651-660.	1.0	31
176	BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. <i>Cell Death and Disease</i> , 2018, 9, 1036.	2.7	31
177	Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. <i>BMC Medicine</i> , 2019, 17, 106.	2.3	31
178	Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma. <i>Theranostics</i> , 2020, 10, 6530-6543.	4.6	31
179	DNA sensing and associated type 1 interferon signaling contributes to progression of radiation-induced liver injury. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1718-1728.	4.8	31
180	Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack. <i>Hepatology</i> , 2023, 77, 109-123.	3.6	31

#	ARTICLE	IF	CITATIONS
181	High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 32.	3.5	30
182	Multiple carcinogenesis contributes to the heterogeneity of HCC. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 13-13.	8.2	30
183	Long non-coding RNA00364 represses hepatocellular carcinoma cell proliferation via modulating p-STAT3-IFIT2 signaling axis. <i>Oncotarget</i> , 2017, 8, 102006-102019.	0.8	30
184	PI-88 inhibits postoperative recurrence of hepatocellular carcinoma via disrupting the surge of heparanase after liver resection. <i>Tumor Biology</i> , 2016, 37, 2987-2998.	0.8	29
185	HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 47121-47135.	0.8	29
186	Long non-coding RNA 00607 as a tumor suppressor by modulating NF- $\kappa$ B p65/p53 signaling axis in hepatocellular carcinoma. <i>Carcinogenesis</i> , 2018, 39, 1438-1446.	1.3	29
187	The progress of immune checkpoint therapy in primary liver cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188638.	3.3	29
188	A New Preoperative Prognostic System Combining CRP and CA199 For Patients with Intrahepatic Cholangiocarcinoma. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e118.	1.3	28
189	Phosphorothioate-Modified AP613-1 Specifically Targets GPC3 when Used for Hepatocellular Carcinoma Cell Imaging. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 376-386.	2.3	28
190	Prognostic Value and Predication Model of Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma. <i>Journal of Cancer</i> , 2019, 10, 5575-5584.	1.2	28
191	HNRNPAB-regulated lncRNA-ELF209 inhibits the malignancy of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2020, 146, 169-180.	2.3	28
192	Positive HBcAb is associated with higher risk of early recurrence and poorer survival after curative resection of HBV-related HCC. <i>Liver International</i> , 2016, 36, 284-292.	1.9	27
193	KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. <i>Journal of Cancer</i> , 2019, 10, 3914-3925.	1.2	27
194	Predicting overall survival of patients with hepatocellular carcinoma using a three-category method based on DNA methylation and machine learning. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 3369-3374.	1.6	27
195	Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT- $\beta$ -catenin signaling pathway. <i>Carcinogenesis</i> , 2020, 41, 130-138.	1.3	27
196	Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus. <i>Gut</i> , 2021, 70, 2159-2171.	6.1	27
197	Autoantibody signature in hepatocellular carcinoma using seromics. <i>Journal of Hematology and Oncology</i> , 2020, 13, 85.	6.9	27
198	Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF- $\kappa$ B signaling pathways synergistically. <i>Clinical and Translational Medicine</i> , 2021, 11, e335.	1.7	27

#	ARTICLE	IF	CITATIONS
199	MicroRNA-34a expression levels in serum and intratumoral tissue can predict bone metastasis in patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 87246-87256.	0.8	27
200	Exosome-depleted MiR-148a-3p derived from Hepatic Stellate Cells Promotes Tumor Progression via ITGA5/PI3K/Akt Axis in Hepatocellular Carcinoma. <i>International Journal of Biological Sciences</i> , 2022, 18, 2249-2260.	2.6	27
201	Decreased Expression of GATA2 Promoted Proliferation, Migration and Invasion of HepG2 In Vitro and Correlated with Poor Prognosis of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e87505.	1.1	26
202	Intrahepatic cholangiocarcinoma patients without indications of lymph node metastasis not benefit from lymph node dissection. <i>Oncotarget</i> , 2017, 8, 113817-113827.	0.8	26
203	Prognostic Nomogram Based on Histological Characteristics of Fibrotic Tumor Stroma in Patients Who Underwent Curative Resection for Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2018, 23, 1482-1493.	1.9	26
204	Circulating Fibroblast Growth Factor 21 Is A Sensitive Biomarker for Severe Ischemia/reperfusion Injury in Patients with Liver Transplantation. <i>Scientific Reports</i> , 2016, 6, 19776.	1.6	25
205	The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined. <i>World Journal of Surgical Oncology</i> , 2016, 14, 131.	0.8	25
206	Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1686-1694.	0.7	25
207	Lymphoid-specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression. <i>Cancer Science</i> , 2019, 110, 2133-2144.	1.7	25
208	Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A single-center, retrospective, propensity-matched study. <i>Clinical and Translational Medicine</i> , 2020, 10, e137.	1.7	25
209	Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection. <i>Annals of Translational Medicine</i> , 2020, 8, 487-487.	0.7	25
210	PNOX Expressed by B Cells in Cholangiocarcinoma Was Survival Related and LAIR2 Could Be a T Cell Exhaustion Biomarker in Tumor Microenvironment: Characterization of Immune Microenvironment Combining Single-Cell and Bulk Sequencing Technology. <i>Frontiers in Immunology</i> , 2021, 12, 647209.	2.2	25
211	Downregulation and pro-apoptotic effect of hypoxia-inducible factor 2 alpha in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 34571-34581.	0.8	25
212	Serum PON1 as a biomarker for the estimation of microvascular invasion in hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 204-204.	0.7	25
213	Mechanisms involved in the activation of C/EBP $\beta$ by small activating RNA in hepatocellular carcinoma. <i>Oncogene</i> , 2019, 38, 3446-3457.	2.6	24
214	Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-programmed Death 1 Immunotherapy for Recurrent Liver Tumors. <i>Liver Transplantation</i> , 2021, 27, 444-449.	1.3	24
215	Donor liver steatosis: A risk factor for early new-onset diabetes after liver transplantation. <i>Journal of Diabetes Investigation</i> , 2017, 8, 181-187.	1.1	23
216	Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis. <i>Journal of Cancer</i> , 2017, 8, 3862-3867.	1.2	23

#	ARTICLE	IF	CITATIONS
217	Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. <i>EBioMedicine</i> , 2020, 62, 103107.	2.7	23
218	Determinants of Long-Term Outcome in Patients Undergoing Simultaneous Resection of Synchronous Colorectal Liver Metastases. <i>PLoS ONE</i> , 2014, 9, e105747.	1.1	23
219	Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinoma. <i>Journal of Pathology</i> , 2017, 243, 407-417.	2.1	22
220	The distribution of immune cells within combined hepatocellular carcinoma and cholangiocarcinoma predicts clinical outcome. <i>Clinical and Translational Medicine</i> , 2020, 10, 45-56.	1.7	22
221	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020, 46, 955-966.	0.5	22
222	Splicing factors: Insights into their regulatory network in alternative splicing in cancer. <i>Cancer Letters</i> , 2021, 501, 83-104.	3.2	22
223	Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world. <i>Annals of Translational Medicine</i> , 2021, 9, 652-652.	0.7	22
224	Spatiotemporal molecular medicine: A new era of clinical and translational medicine. <i>Clinical and Translational Medicine</i> , 2021, 11, e294.	1.7	22
225	Robot-assisted one-stage resection of rectal cancer with liver and lung metastases. <i>World Journal of Gastroenterology</i> , 2015, 21, 2848.	1.4	22
226	Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma. <i>Cancer Letters</i> , 2015, 366, 112-122.	3.2	21
227	Fibrinogen and C-reactive protein score is a prognostic index for patients with hepatocellular carcinoma undergoing curative resection: a prognostic nomogram study. <i>Journal of Cancer</i> , 2018, 9, 148-156.	1.2	21
228	Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. <i>Molecular Oncology</i> , 2022, 16, 549-561.	2.1	21
229	Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance. <i>Tumor Biology</i> , 2016, 37, 9691-9698.	0.8	20
230	Salvage transhepatic arterial embolization after failed stage I ALPPS in a patient with a huge HCC with chronic liver disease: A case report. <i>International Journal of Surgery Case Reports</i> , 2017, 39, 131-135.	0.2	20
231	PDXliver: a database of liver cancer patient derived xenograft mouse models. <i>BMC Cancer</i> , 2018, 18, 550.	1.1	20
232	Efficacy and Safety of Transcatheter Arterial Chemoembolization and Transcatheter Arterial Chemotherapy Infusion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Oncology Research</i> , 2018, 26, 231-239.	0.6	20
233	Platelet activation status in the diagnosis and postoperative prognosis of hepatocellular carcinoma. <i>Clinica Chimica Acta</i> , 2019, 495, 191-197.	0.5	20
234	A microRNA-based prediction model for lymph node metastasis in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 3587-3598.	0.8	20



#	ARTICLE	IF	CITATIONS
235	Generation and characterization of a tetraspanin CD151/integrin $\alpha 6 \beta 2$ -binding domain competitively binding monoclonal antibody for inhibition of tumor progression in HCC. <i>Oncotarget</i> , 2016, 7, 6314-6322.	0.8	20
236	PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy. <i>Journal of Hepatology</i> , 2022, 77, 140-151.	1.8	20
237	A c-Myc/miR-17-5p feedback loop regulates metastasis and invasion of hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 5039-5047.	0.8	19
238	Distinguished prognosis after hepatectomy of HBV-related hepatocellular carcinoma with or without cirrhosis: a long-term follow-up analysis. <i>Journal of Gastroenterology</i> , 2016, 51, 722-732.	2.3	19
239	Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. <i>Science China Life Sciences</i> , 2019, 62, 1138-1143.	2.3	19
240	Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy. <i>Theranostics</i> , 2020, 10, 11921-11937.	4.6	19
241	Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. <i>Cancer Cytopathology</i> , 2020, 128, 733-745.	1.4	19
242	Enhancing soluble expression of sucrose phosphorylase in <i>Escherichia coli</i> by molecular chaperones. <i>Protein Expression and Purification</i> , 2020, 169, 105571.	0.6	19
243	Quantitative acetylome analysis reveals histone modifications that may predict prognosis in hepatitis B-related hepatocellular carcinoma. <i>Clinical and Translational Medicine</i> , 2021, 11, e313.	1.7	19
244	Spatiotemporal molecular imaging is a critical part of spatiotemporal molecular medicine. <i>Clinical and Translational Medicine</i> , 2021, 11, e347.	1.7	19
245	Association of <i>KRAS</i> Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma. <i>JAMA Surgery</i> , 2022, 157, 59.	2.2	19
246	Shanghai Score. <i>Chinese Medical Journal</i> , 2017, 130, 2650-2660.	0.9	18
247	Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. <i>Journal of Translational Medicine</i> , 2019, 17, 203.	1.8	18
248	The mRNA-miRNA-lncRNA Regulatory Network and Factors Associated with Prognosis Prediction of Hepatocellular Carcinoma. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 913-925.	3.0	18
249	Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria: a retrospective analysis. <i>American Journal of Cancer Research</i> , 2015, 5, 450-7.	1.4	18
250	Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy. <i>American Journal of Cancer Research</i> , 2016, 6, 577-86.	1.4	18
251	Novel role of semaphorin 3A in the growth and progression of hepatocellular carcinoma. <i>Oncology Reports</i> , 2017, 37, 3313-3320.	1.2	17
252	Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China. <i>Oncotarget</i> , 2017, 8, 1774-1787.	0.8	17



#	ARTICLE	IF	CITATIONS
253	Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 582-596.	0.7	17
254	CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 705378.	2.2	17
255	Comprehensive Multiple Molecular Profile of Epithelial Mesenchymal Transition in Intrahepatic Cholangiocarcinoma Patients. <i>PLoS ONE</i> , 2014, 9, e96860.	1.1	17
256	Prediction of Post-Operative Liver Dysfunction by Serum Markers of Liver Fibrosis in Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0140932.	1.1	17
257	A novel and validated prognostic nomogram based on liver fibrosis and tumor burden for patients with hepatocellular carcinoma after curative resection. <i>Journal of Surgical Oncology</i> , 2018, 117, 625-633.	0.8	16
258	Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. <i>Journal of Cancer</i> , 2018, 9, 1106-1112.	1.2	16
259	Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis. <i>Molecular Metabolism</i> , 2020, 36, 100966.	3.0	16
260	CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression. <i>Carcinogenesis</i> , 2021, 42, 1293-1303.	1.3	16
261	Sphingosine-1-phosphate transporter spinster homolog 2 is essential for iron-regulated metastasis of hepatocellular carcinoma. <i>Molecular Therapy</i> , 2022, 30, 703-713.	3.7	16
262	The potential of plasma thrombomodulin as a biomarker of portal vein tumor thrombus in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001, 127, 559-564.	1.2	15
263	Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection. <i>BMC Cancer</i> , 2019, 19, 335.	1.1	15
264	TGM3 promotes epithelial-mesenchymal transition and hepatocellular carcinogenesis and predicts poor prognosis for patients after curative resection. <i>Digestive and Liver Disease</i> , 2020, 52, 668-676.	0.4	15
265	DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2020, 18, 176.	0.8	15
266	MicroRNA-19a-3p regulates cell growth through modulation of the PIK3IP1-AKT pathway in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2020, 11, 2476-2484.	1.2	15
267	Targeting HNRNPM Inhibits Cancer Stemness and Enhances Antitumor Immunity in Wnt-activated Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1413-1447.	2.3	15
268	Establishment of monoclonal HCC cell lines with organ site-specific tropisms. <i>BMC Cancer</i> , 2015, 15, 678.	1.1	14
269	Basal Autophagy and Feedback Activation of Akt Are Associated with Resistance to Metformin-Induced Inhibition of Hepatic Tumor Cell Growth. <i>PLoS ONE</i> , 2015, 10, e0130953.	1.1	14
270	Whole-Exome Sequencing-Based Mutational Profiling of Hepatitis B Virus-Related Early-Stage Hepatocellular Carcinoma. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-7.	0.7	14

#	ARTICLE	IF	CITATIONS
271	The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5363-5375.	1.0	14
272	Prognostic impact of lactic dehydrogenase to albumin ratio in hepatocellular carcinoma patients with Child&ndash;Pugh I who underwent curative resection: a prognostic nomogram study. <i>Cancer Management and Research</i> , 2018, Volume 10, 5383-5394.	0.9	14
273	A Novel Risk prediction Model for Patients with Combined Hepatocellular-Cholangiocarcinoma. <i>Journal of Cancer</i> , 2018, 9, 1025-1032.	1.2	14
274	Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score&#x2013;matched survival analysis. <i>Cancer Medicine</i> , 2019, 8, 6933-6944.	1.3	14
275	Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: IS ICC &#x2013;applied prediction model. <i>Cancer Science</i> , 2020, 111, 1084-1092.	1.7	14
276	ROR&#x2013;1 inhibits the proliferation, invasion, and migration of hepatocellular carcinoma MHCC97H via downregulation of chemokine CXCL5. <i>Cytokine</i> , 2020, 129, 155004.	1.4	14
277	Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4094-4094.	0.8	14
278	Activation of pluripotent genes in hepatic progenitor cells in the transition of nonalcoholic steatohepatitis to pre-malignant lesions. <i>Laboratory Investigation</i> , 2017, 97, 1201-1217.	1.7	14
279	KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma. <i>Cancer Cell International</i> , 2022, 22, 128.	1.8	14
280	High level of serum protein DKK1 predicts poor prognosis for patients with hepatocellular carcinoma after hepatectomy. <i>Hepatic Oncology</i> , 2015, 2, 231-244.	4.2	13
281	Significance of PIVKA&#x2013;II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus&#x2013;associated hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 15, 8396-8404.	0.8	13
282	Comparative efficacy and safety between ablative therapies or surgery for small hepatocellular carcinoma: a network meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 935-945.	1.4	13
283	Postoperative &#x2013;fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis. <i>Surgery</i> , 2019, 165, 1161-1167.	1.0	13
284	Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 19-28.	0.7	13
285	Far upstream element-binding protein 1 facilitates hepatocellular carcinoma invasion and metastasis. <i>Carcinogenesis</i> , 2020, 41, 950-960.	1.3	13
286	Laparoscopic hepatectomy enhances recovery for small hepatocellular carcinoma with liver cirrhosis by postoperative inflammatory response attenuation: a propensity score matching analysis with a conventional open approach. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 910-920.	1.3	13
287	CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis. <i>Clinical and Translational Medicine</i> , 2022, 12, e794.	1.7	13
288	Reply to G. Cai et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 2168-2168.	0.8	12

#	ARTICLE	IF	CITATIONS
289	Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis. <i>BMC Cancer</i> , 2017, 17, 762.	1.1	12
290	Autophagy activation contributes to glutathione transferase Mu 1-mediated chemoresistance in hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 16, 346-352.	0.8	12
291	Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1369-1378.	2.0	12
292	&lt;p&gt;Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 5187-5195.	0.9	12
293	Identification of FOS as a Candidate Risk Gene for Liver Cancer by Integrated Bioinformatic Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	12
294	Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2019, 9, 2442-2455.	1.4	12
295	Hepatocellular carcinoma associated with tumor thrombosis in the portal vein: the effects of different treatments. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2003, 2, 513-9.	0.6	12
296	Prognostic nomogram for post-surgical treatment with adjuvant TACE in hepatitis B virus-related hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 58302-58314.	0.8	11
297	A new use for an old index: preoperative high-density lipoprotein predicts recurrence in patients with hepatocellular carcinoma after curative resections. <i>Lipids in Health and Disease</i> , 2017, 16, 123.	1.2	11
298	Serum gamma-glutamyl transferase levels affect the prognosis of patients with intrahepatic cholangiocarcinoma who receive postoperative adjuvant transcatheter arterial chemoembolization: A propensity score matching study. <i>International Journal of Surgery</i> , 2017, 37, 24-28.	1.1	11
299	Differentially expressed miRNAs in hepatocellular carcinoma cells under hypoxic conditions are associated with transcription and phosphorylation. <i>Oncology Letters</i> , 2017, 15, 467-474.	0.8	11
300	Serum IgG4:IgG Ratio Predicts Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection. <i>Journal of Cancer</i> , 2017, 8, 1338-1346.	1.2	11
301	Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. <i>Annals of Translational Medicine</i> , 2020, 8, 1301-1301.	0.7	11
302	Genetic Alterations and Transcriptional Expression of m6A RNA Methylation Regulators Drive a Malignant Phenotype and Have Clinical Prognostic Impact in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 900.	1.3	11
303	BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity. <i>Cell Death and Disease</i> , 2020, 11, 895.	2.7	11
304	Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16690-e16690.	0.8	11
305	Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4. <i>American Journal of Cancer Research</i> , 2018, 8, 1040-1049.	1.4	11
306	Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. <i>British Journal of Cancer</i> , 2020, 123, 92-100.	2.9	10

#	ARTICLE	IF	CITATIONS
307	High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24259.	0.9	10
308	Genetic polymorphisms of the multidrug resistance 1 gene MDR1 and the risk of hepatocellular carcinoma. <i>Tumor Biology</i> , 2015, 36, 7007-7015.	0.8	9
309	The Degree of Lipiodol Accumulation Can Be an Indicator of Successful Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients - in the Case of Transcatheter Arterial Chemoembolization (TACE) and External Beam Radiotherapy (EBRT). <i>Journal of Cancer</i> , 2016, 7, 1413-1420.	1.2	9
310	Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. <i>Oncologist</i> , 2019, 24, 997-1007.	1.9	9
311	Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis. <i>BMC Cancer</i> , 2020, 20, 642.	1.1	9
312	Circulating tumor cell detection and single-cell analysis using an integrated workflow based on Chimerax <sup>®</sup> 120 Platform: A prospective study. <i>Molecular Oncology</i> , 2021, 15, 2345-2362.	2.1	9
313	Laparoscopic vs. Open Repeat Hepatectomy for Recurrent Liver Tumors: A Propensity Score-Matched Study and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 646737.	1.3	9
314	Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma. <i>Hepatology</i> , 2022, 75, 831-846.	3.6	9
315	LOXL4 is downregulated in hepatocellular carcinoma with a favorable prognosis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3892-900.	0.5	9
316	TenEleven translocation <sup>2</sup> inactivation restrains IL <sup>10</sup> -producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma. <i>Hepatology</i> , 2023, 77, 745-759.	3.6	9
317	Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF-1 $\pm$ expression in vivo. <i>Molecular Medicine Reports</i> , 2014, 10, 585-592.	1.1	8
318	Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. <i>Clinica Chimica Acta</i> , 2020, 511, 67-74.	0.5	8
319	Stabilization of p18 by deubiquitylase CYLD is pivotal for cell cycle progression and viral replication. <i>Npj Precision Oncology</i> , 2021, 5, 14.	2.3	8
320	Simulation of portal/hepatic vein associated remnant liver ischemia/congestion by three-dimensional visualization technology based on preoperative CT scan. <i>Annals of Translational Medicine</i> , 2021, 9, 756-756.	0.7	8
321	Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 15126-15138.	1.4	8
322	BRG1 regulates lipid metabolism in hepatocellular carcinoma through the PIK3AP1/PI3K/AKT pathway by mediating GLMP expression. <i>Digestive and Liver Disease</i> , 2022, 54, 692-700.	0.4	8
323	Mucin 1 promotes tumor progression through activating WNT/ $\beta$ -catenin signaling pathway in intrahepatic cholangiocarcinoma. <i>Journal of Cancer</i> , 2021, 12, 6937-6947.	1.2	8
324	Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 871769.	2.2	8

#	ARTICLE	IF	CITATIONS
325	Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children's Hospital APL 2005 protocol (BCH-APL 2005). <i>Pediatric Hematology and Oncology</i> , 2019, 36, 399-409.	0.3	7
326	Dexamethasone for postoperative hyperbilirubinemia in patients after liver resection: An open-label, randomized controlled trial. <i>Surgery</i> , 2019, 165, 534-540.	1.0	7
327	A prospective study of the effect of terlipressin on portal vein pressure and clinical outcomes after hepatectomy: A pilot study. <i>Surgery</i> , 2020, 167, 926-932.	1.0	7
328	BACH2-mediated FOS confers cytarabine resistance via stromal microenvironment alterations in pediatric ALL. <i>Cancer Science</i> , 2021, 112, 1235-1250.	1.7	7
329	Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 13-20.	0.6	7
330	Development and Validation of a Nomogram Based on Perioperative Factors to Predict Post-hepatectomy Liver Failure. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	7
331	Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16610-e16610.	0.8	7
332	eIF3a mediates HIF1 $\alpha$ -dependent glycolytic metabolism in hepatocellular carcinoma cells through translational regulation. <i>American Journal of Cancer Research</i> , 2019, 9, 1079-1090.	1.4	7
333	Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 24.	7.1	7
334	The treatment strategy and outcome for spontaneously ruptured hepatocellular carcinoma: a single-center experience in 239 patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3203-3214.	1.2	7
335	Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 831101.	2.2	7
336	Prognostic significance of nuclear RNA export factor 3 in hepatocellular carcinoma. <i>Oncology Letters</i> , 2014, 7, 641-646.	0.8	6
337	A novel very simple laparoscopic hepatic inflow occlusion apparatus for laparoscopic liver surgery. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 145-152.	1.3	6
338	Laparoscopic Versus Open Left Lateral Segmentectomy for Large Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2019, 29, 513-519.	0.4	6
339	Tfr-Tfh index: A new predictor for recurrence of hepatocellular carcinoma patients with HBV infection after curative resection. <i>Clinica Chimica Acta</i> , 2020, 511, 282-290.	0.5	6
340	Helical IMRT-Based Stereotactic Body Radiation Therapy Using an Abdominal Compression Technique and Modified Fractionation Regimen for Small Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382093700.	0.8	6
341	A High-Accuracy Model Based on Plasma miRNAs Diagnoses Intrahepatic Cholangiocarcinoma: A Single Center with 1001 Samples. <i>Diagnostics</i> , 2021, 11, 610.	1.3	6
342	Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4099-4099.	0.8	6

#	ARTICLE	IF	CITATIONS
343	Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study. <i>Aging</i> , 2019, 11, 11111-11123.	1.4	6
344	Prognostic value of fever grade combined with neutrophil percentage in hepatocellular carcinoma patients presenting fever as the initial manifestation. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6281-6290.	1.0	5
345	Cholecystectomy is associated with higher risk of early recurrence and poorer survival after curative resection for early stage hepatocellular carcinoma. <i>Scientific Reports</i> , 2016, 6, 28229.	1.6	5
346	A retrospective cohort study of preoperative lipid indices and their impact on new-onset diabetes after liver transplantation. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23192.	0.9	5
347	Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, e16163-e16163.	0.8	5
348	Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. <i>Frontiers in Oncology</i> , 2021, 11, 704042.	1.3	5
349	Autophagy and Liver Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1207, 497-528.	0.8	5
350	Clinical activity and safety of penpulimab (Anti-PD-1) with anlotinib as first-line therapy for advanced hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2020, 38, 4592-4592.	0.8	5
351	Plasma MicroRNA Panel Predicts Early Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation. <i>Journal of Cancer</i> , 2021, 12, 7190-7200.	1.2	5
352	Robotic procedure versus open surgery for simultaneous resection of colorectal cancer with liver metastases: Short-term outcomes of a randomized controlled study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3575-3575.	0.8	5
353	Low expression is associated with poor prognosis in patients with hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2017, 7, 2465-2477.	1.4	5
354	Reduced selenium-binding protein 1 correlates with a poor prognosis in intrahepatic cholangiocarcinoma and promotes the cell epithelial-mesenchymal transition. <i>American Journal of Translational Research (discontinued)</i> , 2018, 10, 3567-3578.	0.0	5
355	Integrated Bioinformatics analysis and clinical validation reveals that high expression of mucin 1 in intrahepatic cholangiocarcinoma predicts recurrence after curative resection. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	5
356	Retrospective study of hepatocellular adenomas based on the phenotypic classification system: A report from China. <i>Histology and Histopathology</i> , 2014, 29, 243-9.	0.5	5
357	Multimodality treatment of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, S315-S319.	1.4	4
358	Effect of interleukin-2 receptor antagonists on new-onset diabetes after liver transplantation: A retrospective cohort study. <i>Journal of Diabetes</i> , 2016, 8, 579-587.	0.8	4
359	Surgical Resection plus Radiofrequency Ablation versus Radical Surgery for Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Journal of Cancer</i> , 2019, 10, 3933-3940.	1.2	4
360	A Semi-Automatic Step-by-Step Expert-Guided LI-RADS Grading System Based on Gadoteric Acid-Enhanced MRI. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 671-683.	1.8	4



#	ARTICLE	IF	CITATIONS
361	GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2020, 10, 3705-3720.	1.4	4
362	Long-term outcomes and prognosis for patients with sarcomatoid hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 394-394.	0.7	4
363	Higher intratumor than peritumor expression of DUSP6/MKP-3 is associated with recurrence after curative resection of hepatocellular carcinoma. <i>Chinese Medical Journal</i> , 2014, 127, 1211-7.	0.9	4
364	SOX2/p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelial-mesenchymal transition and mitochondrial function maintenance. <i>Cancer Medicine</i> , 2023, 12, 459-471.	1.3	4
365	Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: Updated data from an open-label, single-arm, multicenter phase II study (CIBI375A201 study).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16183-e16183.	0.8	4
366	Low expression of exosomal miR-150 predicts poor prognosis in colorectal cancer patients after surgical resections. <i>Carcinogenesis</i> , 2022, 43, 930-940.	1.3	4
367	Naive Treg-like CCR7+ mononuclear cells indicate unfavorable prognosis in hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 9909-9917.	0.8	3
368	Coagulopathy associated with poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection. <i>BioScience Trends</i> , 2017, 11, 469-474.	1.1	3
369	A novel preoperative predictive model of 90-day mortality after liver resection for huge hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 774-774.	0.7	3
370	Profiles of alternative splicing landscape in breast cancer and their clinical significance: an integrative analysis based on large-sequencing data. <i>Annals of Translational Medicine</i> , 2021, 9, 58-58.	0.7	3
371	Effect of postoperative apatinib treatment after resection of hepatocellular carcinoma with portal vein invasion: A phase II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 514-514.	0.8	3
372	Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2022, , .	0.9	3
373	Application of circulating tumor DNA for prediction and surveillance of tumor recurrence after liver transplantation: A pilot study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16149-e16149.	0.8	3
374	TALENTop: A multicenter, randomized study evaluating the efficacy and safety of hepatic resection for selected hepatocellular carcinoma with macrovascular invasion after initial atezolizumab plus bevacizumab treatment.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4175-TPS4175.	0.8	3
375	Association of hepatitis status with surgical outcomes in patients with dual hepatitis B and C related hepatocellular carcinoma. <i>Infectious Agents and Cancer</i> , 2017, 12, 28.	1.2	2
376	Differential network analysis depicts regulatory mechanisms for hepatocellular carcinoma from diverse backgrounds. <i>Future Oncology</i> , 2019, 15, 3917-3934.	1.1	2
377	Reply to "Are the 5-hydroxymethylcytosine-based wd-scores really superior over Î±-fetoprotein for the early diagnosis of hepatocellular carcinoma?" <sup>TM</sup> . <i>Gut</i> , 2020, 69, 1903-1904.	6.1	2
378	Limited bias effect of intratumoral heterogeneity on genetic profiling of hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 112-120.	0.6	2



#	ARTICLE	IF	CITATIONS
379	Factors influencing adjuvant treatment decision making among Chinese patients with hepatocellular carcinoma (HCC): Results of a patient survey.. <i>Journal of Clinical Oncology</i> , 2021, 39, 346-346.	0.8	2
380	Development of an Eight-gene Prognostic Model for Overall Survival Prediction in Patients with Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	2
381	Newly detected liver nodules with a history of colorectal cancer: are they metastatic? Review of 2,632 cases in a single center. <i>Annals of Translational Medicine</i> , 2021, 9, 1079-1079.	0.7	2
382	Multimodality treatment of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, S315.	1.4	2
383	Clinical validation of a multicancer detection blood test by circulating cell-free DNA (cfDNA) methylation sequencing: The THUNDER study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10544-10544.	0.8	2
384	Adjuvant lenvatinib after radical resection in patients with hepatocellular carcinoma (HCC): Preliminary analysis of a prospective, multi-center, single-arm study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16158-e16158.	0.8	2
385	Association of intrinsic pathways with altered tumor immune infiltration in hepatocellular carcinoma: New targets for combining immune therapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e219.	1.7	1
386	Comparison of immune profiles between hepatocellular carcinoma subtypes. <i>Biophysics Reports</i> , 2020, 6, 19-32.	0.2	1
387	Radiological response as a predictor of pathological response to combined tyrosine kinase inhibitor (TKI) and anti-PD-1 antibodies in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16144-e16144.	0.8	1
388	Analysis of epigenomic signatures in cell-free DNA (cfDNA) from cancer patients and high-risk controls: A blinded test cohort of THUNDER-II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e22518-e22518.	0.8	1
389	Development of a novel liquid biopsy test to diagnose and locate gastrointestinal cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1557-1557.	0.8	1
390	Genome-wide plasma cell-free DNA methylation profiling to identify high-performing biomarkers for early detection of hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4600-4600.	0.8	1
391	C5aR correlated with the dissemination capacity of circulating tumor cells in hepatocellular carcinoma by targeting INHBA-p-smad2/3-EMT/MMPs axis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16649-e16649.	0.8	1
392	Integrated Bioinformatics analysis and clinical validation reveals that high expression of mucin 1 in intrahepatic cholangiocarcinoma predicts recurrence after curative resection. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 50.	0.8	1
393	TM2D1 contributes the epithelial-mesenchymal transition of hepatocellular carcinoma via modulating AKT/ $\beta$ 2-catenin axis. <i>American Journal of Cancer Research</i> , 2021, 11, 1557-1571.	1.4	1
394	Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 847263.	2.2	1
395	Clinical practice status of the adjuvant therapy in hepatocellular carcinoma (HCC): A survey of Chinese hepatobiliary surgeons.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16127-e16127.	0.8	1
396	AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4172-TPS4172.	0.8	1

#	ARTICLE	IF	CITATIONS
397	“Three-Grade Criteria” of radical resection for primary liver cancer. Chinese Journal of Clinical Oncology, 2005, 2, 820-823.	0.0	0
398	Reply to Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus-positive hepatocellular carcinoma. Cancer, 2010, 116, 2501-2502.	2.0	0
399	Predictive gene-expression score for follicular lymphoma. Lancet Oncology, The, 2018, 19, e278.	5.1	0
400	Increase of Portal Vein Pressure Gradient After Hepatectomy Predicts Post-operative Liver Dysfunction. Surgical Innovation, 2022, 29, 145-153.	0.4	0
401	Abstract 1456: The safety and efficacy of lenvatinib in preventing early recurrence after liver transplantation for hepatocellular carcinoma beyond Milan criteria: A single-center, retrospective, propensity-matched study. , 2021, , .		0
402	Sintilimab plus IBI305 for hepatocellular carcinoma “ Author's reply. Lancet Oncology, The, 2021, 22, e388.	5.1	0
403	Impact of deviated balance of regulatory and cytotoxic T cells on release and reseeding of circulating tumor cells in hepatocellular carcinoma.. Journal of Clinical Oncology, 2013, 31, e22133-e22133.	0.8	0
404	Use of nanocurcumin to inhibit proliferation and metastases of hepatocellular carcinoma via NF- $\kappa$ B mediated matrix metalloproteinase-9 downregulation.. Journal of Clinical Oncology, 2013, 31, e22103-e22103.	0.8	0
405	Impact of early tumor shrinkage on clinical outcome in KRAS wild-type colorectal liver-limited metastases treated with cetuximab plus chemotherapy: Lessons from a randomized controlled trial.. Journal of Clinical Oncology, 2013, 31, 3610-3610.	0.8	0
406	In vitro and clinical study of association between macrophage and epithelial-mesenchymal transition in hepatocellular carcinoma cells.. Journal of Clinical Oncology, 2014, 32, e15149-e15149.	0.8	0
407	The biological characteristics and kinetics of circulating tumor cells in hepatocellular carcinoma undergoing surgical interventions.. Journal of Clinical Oncology, 2014, 32, e22013-e22013.	0.8	0
408	Effect of HnRNPAB on epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by transcriptionally activating snail.. Journal of Clinical Oncology, 2014, 32, e22004-e22004.	0.8	0
409	The heterogeneity and clinical relevance of circulating tumor-initiating cells in hepatocellular carcinoma using an integrated immunomagnetic-microfluidic platform.. Journal of Clinical Oncology, 2014, 32, e15132-e15132.	0.8	0
410	CD13-HDAC5 signaling axis promotes hepatocellular carcinoma and sorafenib resistance by activating NF-KB.. Journal of Clinical Oncology, 2018, 36, e16144-e16144.	0.8	0
411	High spatiotemporal heterogeneity, clonal selection and neoantigen evolution in acquired sorafenib-resistant patient-derived xenograft models of hepatocellular carcinoma.. Journal of Clinical Oncology, 2019, 37, e15641-e15641.	0.8	0
412	Mei-Shin Shih: a surgeon, master, and mentor. Journal of Thoracic Disease, 2014, 6, 1371-3.	0.6	0
413	BRCA1-associated protein 1 serves as a tumor suppressor in hepatocellular carcinoma by deubiquitinating and stabilizing PTEN. American Journal of Cancer Research, 2021, 11, 2044-2061.	1.4	0
414	AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, TPS488-TPS488.	0.8	0

#	ARTICLE	IF	CITATIONS
415	110. A Phase 3, Multicenter, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal Infections. <i>Open Forum Infectious Diseases</i> , 2021, 8, S67-S68.	0.4	0
416	Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma: Data from an open-label, multicenter phase II basket study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18031-e18031.	0.8	0
417	Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3577-3577.	0.8	0
418	Discovery and clinical validation of cost-effective noninvasive early detection of hepatocellular carcinoma (HCC) through circulating tumor DNA (ctDNA) methylation signature.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4103-4103.	0.8	0